share this article!

2021/02/18 BRAZIL: An Intellia Therapeutics logo is shown on a… [+] smartphone with a stock market image in the backdrop in this photo illustration. (Image courtesy of Rafael Henrique/SOPA Images/LightRocket/Getty Images)
Getty Images/SOPA Images/LightRocket
[7/01/2021] [Updated: 7/01/2021] Update on the NTLA After the company announced positive data from early clinical trials for NTLA-2001, an experimental treatment for transthyretin amyloidosis using CRISPR gene editing, the stock price of Intellia Therapeutics (NASDAQ: NTLA), a biotechnology company developing treatments using a CRISPR gene-editing system, has risen by 70% in just two trading days. After a single infusion, the medication drastically lowered the disease-causing protein, according to the findings. This is a watershed moment for Intellia and other gene-editing stocks, as it paves the path for the use of gene editing technology to treat a variety of ailments. Other options under development by Intellia include NTLA-2002, a treatment for hereditary angioedema, and NTLA-5001, a treatment for acute myeloid leukemia.
Despite the fact that NTLA stock has already risen by 70% this week, we feel that, given the current momentum and a substantial positive event surrounding NTLA-2001, the stock will likely continue to rise in the future. Intellia will now engage with the US Food and Drug Administration to develop a roadmap for NTLA-2001 registration.
But what if you wanted to own NTLA stock for a shorter or longer length of time? How would the returns change? On the Trefis Machine Learning Engine, you may test the response and many other combinations to see if Intellia Therapeutics’ stock will rise after a decline. You can evaluate the likelihood of recovery across time intervals of a quarter, month, or even a single day!
[3/17/2021] [Updated] The price of NTLA has risen.
Intellia Therapeutics (NASDAQ: NTLA), a biotechnology firm researching therapies based on the CRISPR gene-editing method, has witnessed a healthy 15% increase in the last five trading days, and a 6% increase in the last ten trading days. Despite the recent increase, we anticipate the stock will continue to rise in the near term. The company’s announcement of pre-clinical evidence for its non-viral genome editing tool is largely responsible for the recent rise. The results supports the company’s sickle cell disease therapy option, which avoids the need for bone marrow transplantation.
In terms of the recent rally, the 15 percent increase in NTLA stock over the last five days compares to a 2.6 percent increase in the S&P 500 index. Is the stock of NTLA set to surge much higher now? That’s how it appears. Based on our machine learning research of stock price movements over the previous few years, we predict that NTLA stock has a strong 64 percent chance of rising in the coming month (twenty-one trading days). For more information, see our Intellia Therapeutics Stock Chances of Rise study.
ADDITIONAL INFORMATION FOR YOU
Days 1–5: NTLA 15% vs. S&P500 2.6 percent; Outperformed the market (9 percent likelihood event)
In comparison to the broader market, Intellia Therapeutics stock climbed 15% over a five-day trading period ending 3/16/2021. (S&P500) a 2.6 percent increase
A change of 15% or more over five trading days is a 9% chance event, and it has happened 111 times out of 1218 times in the last five years.

NTLA 5.8 percent in ten days, versus. 2.8 percent for the S&P500; Market outperformed (40 percent likelihood event)
In comparison to the broader market, Intellia Therapeutics stock climbed 5.8% in the last 10 trading days (two weeks) (S&P500) a 2.8 percent increase
A move of 5.8% or more over 10 trading days is a 40% chance event, and it has happened 482 times out of 1202 times in the last five years.

Twenty-one days: NTLA -4 percent vs. S&P500 1.1 percent; market underperformer (27 percent likelihood event)
In comparison to the broader market, Intellia Therapeutics stock has dropped 4.0 percent in the previous twenty-one trading days (one month) (S&P500) a 1.1 percent increase
A move of 4% or more over twenty-one trading days is a 27 percent chance occurrence, and it has happened 309 times out of 1160 times in the last five years.

While the stock of NTLA may recover, the year 2020 has produced numerous pricing discontinuities that could provide lucrative trading opportunities. For example, the stock valuation for Abbott vs. Vertex is very counter-intuitive.
Here you may find all of Trefis’ Featured Analyses and Trefis Data./nRead More

share this article!